Use of a Lipopeptide or Lipoprotein as an Adjuvant in Therapeutic or Prophylactic Vaccinations
AssigneeHelmholtz-Zentrum fuer Infektionsforschung GmbH
InventorsCarlos Alberto Guzman, Peter Muhlradt
Life of this patent
Estimating the term…
Abstract
Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bis-palmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.
Claims11
1-11. (canceled)
A method of vaccinating an animal or human in need thereof, comprising the steps of:
- providing said animal or human, via mucous membranes of said animal or human, with an antigen;
- and
- providing said animal or human, via mucous membranes of said animal or human, with an adjuvant in the form of a lipopeptide or lipoprotein of the structure (I)
- where
- R1 and R2, which may be identical or different, are C7-25-alkyl, C7-25-alkenyl or C7-25-alkynyl,
- X is S, O or CH2,
- R3 and R4 are independently of one another H or methyl and
- Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,
- and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur).
Dependencies are inferred from the claim text.